List of Models
|
Model |
Cancer type |
Xenograft |
Syngeneic |
|
Subcutaneous |
Bladder |
UM-UC-3 |
|
|
Breast |
MCF7, MDA-MB-231 |
4T1, 4T1-Luc-TdTomato |
|
|
Burkitt’s lymphoma |
Raji |
||
|
Cervix |
A431, CaSki |
||
|
Colon |
DLD-1, HCT-8, HCT-15, HCT-116, HT-29, LoVo, RKO, SW620 |
CT26, MC38 |
|
|
Kidney |
SN12C |
||
|
Leukemia |
K562 |
||
|
Liver |
Hep3B, HepG2, HepG2-Red-Fluc, Huh7, Huh7-Luc, SK-Hep1 |
||
|
Lung |
A549, H69, H146, H209, H460, H1299 |
LLC1 |
|
|
Melanoma |
UACC-62 |
B16-F10 |
|
|
Ovary |
OVCAR3, OVCAR-3-Luc, SKOV3, SNU251 |
||
|
Pancreas |
AsPC-1, AsPC-1-Luc, BxPC-3, BxPC-3-Luc2, CaPan-1, MiaPaCa2, QGP1 |
PAN 02 | |
|
Prostate |
DU145, PC3 |
TRAMP-C1 | |
|
Stomach |
NCI-N87 |
|
Orthotopic |
Breast |
4T1-Luc-TdTomato |
|
|
Colon |
HCT116-Red, HT-29-Luc |
|
|
|
Leukemia |
MOLM-13, MV4-11, Raji |
||
|
Liver |
HepG2-Red-Fluc |
||
|
Lung |
A549-Luc, NCI-H226-Luc, NCI-H1703-Luc |
||
|
Ovary |
ES-2-Luc, OVCAR-3-Luc, SKOV3-Luc |
ID8-Luc |
|
|
Pancreas |
AsPC-1-Luc, BxPC-3-Luc |
PAN02 |
|
|
Prostate |
TRAMP-C1 |
|
Metastasis |
Breast |
4T1-Luc-TdTomato (Intracardiac Injection), 4T1-Luc-TdTomato (Intravenous Injection) |
|
|
Colon |
SW620-Luc |
||
|
Leukemia |
WEHI-3 |
||
|
Ovary |
ES-2-Luc (Orthotopic Injection), OVCAR-3-Luc (Intraperitoneal Injection), SK-OV-3-Luc (Intraperitoneal Injection) |
|
Spontaneous Model |
||
|
Lung |
Lung (Mutation: p53/ras) |
|
Genetically Engineered Mouse |
||
|
Lung |
Ba/F3/Her2 insertion cell line, EGFR mutant(L858R+T790M +C797S)-induced lung cancer in mouse |
|
Humanized Mouse (hHSC) |
Endometrial |
Hec-1A subcutaneous xenograft, Ishikawa subcutaneous xenograft |
|
Liver |
Hep3B-Luc orthotopic xenograft, Huh-7-Luc orthotopic xenograft, HepG2. 2.15 orthotopic xenograft |
|
|
Ovary |
ES-2-Luc orthotopic xenograft, OVCA3-Luc orthotopic xenograft |
|
|
Pancreas |
ASPC-1-Luc orthotopic xenograft, BxPC-3-Luc orthotopic xenograft |
Service
- Customized study design
- Tumor growth inhibition/delay study
- Single treatment
- Combination treatment
- Kaplan-Meier survival analysis
- Metastasis inhibition study
- Radiotherapy response study
- Histological analysis
- Tissue preparation, IHC, TUNEL, DNA/RNA/protein extraction
- Histopathology
- MOA (Mechanism of Action) & POC (Proof of Concept) validation
- In vivo imaging study
- Utilizing MRI, PET, PET-MR, CT, and Optical imaging
- PD, tissue distribution
Service example
In vivo evaluation of anticancer efficacy
in a colorectal cancer subcutaneous xenograft model